Acta Pharmacologica Sinica

Acta Pharmacologica Sinica is a monthly peer-reviewed journal published in English by Springer Nature as the official journal of the Chinese Pharmacological Society and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, launched in 1980 and covering all areas of pharmacology and the life sciences, with a 2025 Journal Impact Factor of 10.4《中国药理学报》（Acta Pharmacologica Sinica）是（Springer Nature）出版的英文月刊同行评审期刊，为中国药理学会与中国科学院上海药物研究所的官方期刊，1980 年创刊，涵盖药理学与生命科学各领域，2025 年影响因子为 10.4。

Scope

• The journal encourages submissions from all areas of pharmacology and the life sciences, with topics of particular interest including anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics and pharmacokinetics该刊征集药理学与生命科学各领域的稿件，特别关注的选题包括抗癌药理、心血管与肺药理、临床药理、药物发现、胃肠与肝药理、泌尿生殖与肾内分泌药理、免疫药理与炎症、分子与细胞药理、神经药理、药剂学与药代动力学。

• It publishes original research articles and reviews, and a recent open access study presented amyloid-beta fibrils as active contributors to synaptic dysfunction in Alzheimer disease该刊发表原创研究论文与综述，近期一篇开放获取研究提出β淀粉样蛋白纤维是阿尔茨海默病突触功能障碍的主动参与者。^[1]

• Peer review is international, and the publisher reports twenty-five days from submission to first decision该刊实行国际同行评审，出版方报告从投稿到首次决定为 25 天。

• Authors may choose the traditional subscription model or the gold open access route, with an article processing charge of 4590 US dollars, 2990 pounds or 3890 euros, and open access articles appear under a CC BY or CC BY-NC-ND licence作者可选择传统订阅模式或金色开放获取路径，文章处理费为 4590 美元、2990 英镑或 3890 欧元，开放获取文章以（CC BY）或（CC BY-NC-ND）许可发表。

• Its 2025 metrics include a Journal Impact Factor of 10.4, a five-year Journal Impact Factor of 10.8, a Source Normalized Impact per Paper of 1.931 and an SCImago Journal Rank of 2.691其 2025 年指标包括影响因子 10.4、五年影响因子 10.8、（SNIP）1.931 与（SJR）2.691。

• The journal is abstracted and indexed in the Science Citation Index Expanded, Scopus, MEDLINE, EMBASE, Current Contents, Chemical Abstracts Service, the Chinese Science Citation Database and PubMed Central该刊被（SCIE）、（Scopus）、（MEDLINE）、（EMBASE）、（Current Contents）、（CAS）、中国科学引文数据库与（PubMed Central）收录。

History

• The journal was launched in September 1980 as an English-language monthly sponsored by the Chinese Pharmacological Society and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences该刊于 1980 年 9 月创刊，为中国药理学会与中国科学院上海药物研究所主办的英文月刊。

• It entered the Science Citation Index in 1985, only five years after its launch该刊于 1985 年进入（SCI），创刊仅 5 年。

• Since 2009 the journal has been co-published with Springer Nature, and the full text is hosted on the Nature Portfolio platform自 2009 年起，该刊与（Springer Nature）合作出版，全文托管于（Nature Portfolio）平台。

• Its impact factor has climbed steadily in recent years, recorded as 6.15 for 2021, 7.169 for 2022, 8.4 for 2024 and 10.4 for 2025其影响因子近年稳步上升，2021 年为 6.15，2022 年为 7.169，2024 年为 8.4，2025 年为 10.4。

• The publisher recorded 3,887,964 downloads of journal content in 2025 and 1,137 Altmetric mentions出版方统计 2025 年该刊内容下载量近 389 万次，（Altmetric）提及 1137 次。

• In 2025 the journal was ranked in the top quartile of pharmacology and pharmacy journals worldwide and received an editorial excellence award from the publisher based on author satisfaction surveys in 2024 and 20252025 年该刊位列全球药理与药学类期刊前四分位，并因 2024 与 2025 年作者满意度调查获出版方编辑卓越奖。

Editors

• Professor Jian Ding, a tumour pharmacologist and academician of the Chinese Academy of Engineering at the Shanghai Institute of Materia Medica, serves as editor-in-chief主编为中国科学院上海药物研究所的肿瘤药理学家、中国工程院院士（Jian Ding）研究员。

• Ten associate editors support the editor-in-chief, among them Guan-hua Du of the Chinese Academy of Medical Sciences and Peking Union Medical College, Dayue Duan of the University of Nevada, Meiyu Geng and Qiang Yu of the Shanghai Institute of Materia Medica, and Bao-feng Yang of Harbin Medical University10 位副主编协助主编工作，包括中国医学科学院与北京协和医学院的（Guan-hua Du）、内华达大学的（Dayue Duan）、中国科学院上海药物研究所的（Meiyu Geng）与（Qiang Yu）以及哈尔滨医科大学的（Bao-feng Yang）。

• The international editorial board spans the coverage of the journal and includes members from China, the United States, Japan, South Korea, Canada, Australia, Germany, Belgium, Austria and the United Kingdom国际编委会覆盖该刊全部学科范围，成员来自中国、美国、日本、韩国、加拿大、澳大利亚、德国、比利时、奥地利与英国。

• Board members include Alexei Verkhratsky of the University of Manchester, Hartmut Wekerle of the Institute of Clinical Neuroimmunology in Munich, Takao Yamori of Teikyo University and Burton Yang of the University of Toronto编委成员包括曼彻斯特大学的（Alexei Verkhratsky）、慕尼黑临床神经免疫学研究所的（Hartmut Wekerle）、帝京大学的（Takao Yamori）与多伦多大学的（Burton Yang）。

• The journal is a member of the Committee on Publication Ethics and follows its principles该刊是国际出版伦理委员会（COPE）成员，遵循其原则。

• The partner institute behind the journal, the Shanghai Institute of Materia Medica, was founded in 1932 as the drug research institute of the Chinese Academy of Sciences该刊的依托机构中国科学院上海药物研究所创建于 1932 年，是中国科学院下属的药物研究机构。